Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Cassava Sciences Inc (NQ: SAVA )

21.21 -0.62 (-2.84%)
Streaming Delayed Price Updated: 3:11 PM EDT, May 8, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Cassava Sciences Inc

< Previous 1 2
...
24 25 26 27 28 29 30 31 Next >
Neurodegenerative Disease, Cancer Stocks Among Top Biotech Gainers In 2021
Biotech stocks underperformed the broader market in the first half of 2021, with the iShares Nasdaq Biotechnology ETF (NASDAQ: IBB) advancing about 8% year-to-date ... 
Via Benzinga
This Biotech Stock Is Beating GameStop
Now the question is whether the gains are here to stay. 
Via The Motley Fool
Is It Too Late to Buy Cassava Sciences Stock?
Just because the stock has had a massive run doesn't mean its biggest gains are behind it. 
Via The Motley Fool
PreMarket Prep Recap: The 4 Stocks Dennis Dick Bought Yesterday
On Wednesday’s PreMarket Prep, co-hosts Joel Elconin and Dennis Dick discussed the bullish chart setups in several tech stocks. ... 
Via Benzinga
Why Cassava Sciences Stock Soared Today
Investors applauded the company's update on its clinical programs. 
Via The Motley Fool
Why Cassava Sciences Shares Are Moving Today
Cassava Sciences Inc (NASDAQ:SAVA) shares are trading high... 
Via Benzinga
Alzheimer’s Treatment Market Is Anticipated To Reach $2 Billion By The End Of 2027
Via FinancialNewsMedia
Topics Death
Exposures Death
Could Cassava Sciences Be a Millionaire-Maker Stock?
Can this biotech underdog develop an Alzheimer's drug investors can count on? 
Via The Motley Fool
44 Biggest Movers From Yesterday
Gainers Alfi, Inc. (NASDAQ: ALF) shares jumped 108.9% to settle at $16.29 on Tuesday following exclusive Benzinga reporting the company will buyback up to $2 million of its... 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers Anavex Life Sciences (NASDAQ:AVXL) stock increased by 17.07% to $25.92 during Tuesday's regular session. As of 12:33 EST, this security is trading at a volume... 
Via Benzinga
The Daily Biotech Pulse: Sanofi, Translate Bio Start Early Stage Seasonal Flu Vaccine Study, Dr. Reddy's Launches Generic Vascepa, Halozyme Strikes Licensing Deal
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 21) Agios Pharmaceuticals, Inc... 
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Gainers Anavex Life Sciences (NASDAQ:AVXL) shares moved upwards by 17.07% to $25.92 during Monday's regular session. Anavex Life Sciences's stock is trading at a... 
Via Benzinga
Cassava Sciences Stock Gains After Outlining Clinical Development Progress For Lead Alzheimer's Candidate
Cassava Sciences Inc (NASDAQ: SAVA) has announced a mid-year update highlighting clinical development progress and providing guidance on upcoming data releases for... 
Via Benzinga
These 2 Biotech Stocks Are Up 1,000% This Year
New approaches to treating Alzheimer's could mean even bigger gains in the future. 
Via The Motley Fool
Why Anavex Stock Nearly Round-Tripped Its Double-Digit Gain This Week
Researchers featured a pair of Anavex Life Sciences drugs in a paper on Alzheimer's disease this week, but AVXL stock plunged on Tuesday. 
Via Investor's Business Daily
Where Will Biogen Be in 1 Year?
The controversy never ends with this biotech's new Alzheimer's drug. 
Via The Motley Fool
Exposures Product Safety
Tuesday Talk: Action!
U.S. stock markets started the week in continued action mode. The S&P 500 closed at 4,255, up nearly 8 points, the Dow closed at 34,394, down 85 points and the Nasdaq Composite closed at 14,174, up... 
Via Talk Markets
Topics Stocks
Exposures US Equities
64 Biggest Movers From Friday
Gainers Kanzhun Limited (NASDAQ: BZ) shares climbed 95.8% to close at $37.20 on Friday after the company priced its IPO at $19 per share. Novan, Inc. (NASDAQ: NOVN) shares gained... 
Via Benzinga
Topics Initial Public Offering
Exposures Securities Market
Biotechs Ready To Roar
The biggest event last week was the FDA decision to approve Biogen's drug aducanumab, a treatment for Alzheimer's disease. The decision will reverberate across the industry and the healthcare sector... 
Via Talk Markets
Exposures Product Safety
46 Stocks Moving In Friday's Mid-Day Session
Gainers Kanzhun Limited (NASDAQ: BZ) shares surged 77.4% to $33.70 after the company priced its IPO at $19 per share. Novan, Inc. (NASDAQ: NOVN) shares jumped 73.3% to $15.67... 
Via Benzinga
Topics Initial Public Offering
Exposures Securities Market
8 Health Care Stocks Showing Unusual Options Activity In Today's Session
This unusual options alert can help traders track potentially big trading opportunities. Traders often look for circumstances when the market estimation of an option diverges away... 
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Gainers Novan (NASDAQ:NOVN) stock rose 71.04% to $15.46 during Friday's regular session. As of 12:30 EST, Novan's stock is trading at a volume of 109.3 million,... 
Via Benzinga
28 Stocks Moving in Friday's Pre-Market Session
Gainers Amesite Inc. (NASDAQ: AMST) rose 138% to $6.60 in pre-market trading after surging over 25% on Thursday. Chemomab Therapeutics Ltd. (NASDAQ: CMMB) rose 37.5% to $27.50... 
Via Benzinga
Ignore Biogen: 3 Reasons These Stocks Will Be Better Alzheimer's Investments
Data doesn't lie. These companies have the potential to quickly steal the spotlight. 
Via The Motley Fool
Exposures Product Safety
Biogen Snagged: Will Hefty Price Tag Hinder Alzheimer's Drug Use?
Biogen stock dipped Tuesday as analysts questioned how much use its potential blockbuster Alzheimer's treatment, Aduhelm, would ultimately secure. 
Via Investor's Business Daily
Why Centene Stock Was Up 19% in May
New executives and confirmation that an acquisition will close soon sparked a rally in the shares. 
Via The Motley Fool
Why Cassava Sciences Was Up 15% in May
Thanks to key funding, its Alzheimer's drug is on track even after Biogen's historic approval. 
Via The Motley Fool
Forget Biogen: These 2 Alzheimer's Drug Stocks Could Make You Rich
There are better options for investors looking to profit from potential Alzheimer's disease treatments. 
Via The Motley Fool
Exposures Product Safety
Biogen Wins Landmark Alzheimer's Approval: 5 Things To Know About Aducanumab
The FDA approved Biogen's Alzheimer's treatment, aducanumab, on Monday — though Biogen stock remained halted into the long-awaited decision. 
Via Investor's Business Daily
Exposures Product Safety
Annovis Bio Stock Rockets As Alzheimer's Drug Tops Biogen, Cassava Sciences
Annovis Bio said Friday its experimental Alzheimer's and Parkinson's treatment improved cognition in less than a month, leading ANVS stock to soar. 
Via Investor's Business Daily
< Previous 1 2
...
24 25 26 27 28 29 30 31 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.